Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jeroen Paul Jansen

Associate Professor

University of California, San Francisco

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

About

Jeroen Paul Jansen is an Associate Professor at the University of California San Francisco, USA. His research focuses on health economics, with recent publications addressing comparative effectiveness in multiple myeloma treatments, survival function analysis through multivariate network meta-analysis, and the economic impacts of kidney graft failure. He is dedicated to advancing methodologies in health-related research.

Articles (12)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Mazyar Shadman

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

James Buchanan

Senior Lecturer

Queen Mary University of London

UNITED KINGDOM

View details

Tara A Lavelle

Tufts Medical Center

UNITED STATES

View details

Maarten IJzerman

Full professor

Erasmus University Rotterdam

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jeroen Paul Jansen

Research Interests

Make your next move.

Explore related searches

About

Articles (12)

Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.

The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study.

Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.

Distributional Cost-Effectiveness Analysis in Genomic Medicine

Augmented two-stage estimation for treatment switching in oncology trials: Leveraging external data for improved precision.

Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions.

Population-adjusted unanchored indirect comparisons of cancer therapies with borrowing of pan-tumor information.

One-step parametric network meta-analysis models using the exact likelihood that allow for time-varying treatment effects.

The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis.

Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.

Multivariate network meta-analysis of survival function parameters.

The economic burden of kidney graft failure in the United States.

Collaborators (4)

Mazyar Shadman

James Buchanan

Tara A Lavelle

Maarten IJzerman

Make your next move.